ES2088584T3 - Productos de 1h-1,2,4-triazol substituidos por arilheteroarilalquilo en 1 para el tratamiento de trastornos circulatorios. - Google Patents

Productos de 1h-1,2,4-triazol substituidos por arilheteroarilalquilo en 1 para el tratamiento de trastornos circulatorios.

Info

Publication number
ES2088584T3
ES2088584T3 ES92914808T ES92914808T ES2088584T3 ES 2088584 T3 ES2088584 T3 ES 2088584T3 ES 92914808 T ES92914808 T ES 92914808T ES 92914808 T ES92914808 T ES 92914808T ES 2088584 T3 ES2088584 T3 ES 2088584T3
Authority
ES
Spain
Prior art keywords
butyl
butynyl
butenyl
difluoro
cyclohexylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92914808T
Other languages
English (en)
Inventor
David B Reitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2088584T3 publication Critical patent/ES2088584T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UNA CLASE DE 1-ARILHETEROARILALQUILO 1H-1,2,4 TRIAZOLO SUSTITUIDOS PARA USO EN TRATAMIENTO DE TRASTORNOS CIRCULATORIOS TALES COMO HIPERTENSION. COMPUESTOS DE INTERES PARTICULAR SON ANTAGONISTAS DE ANGIOTENSINA II DE LA FORMULA (I) EN DONDE A SE SELECCIONA DE (1, 2, 3, 4, 5 Y 6), EN DONDE M ES UNO; EN DONDE R1 SE SELECCIONA DE METILO, ETILO, N-PROPILO, ISOPROPILO, N-BUTILO, SEC-BUTILO, ISOBUTILO, TER-BUTILO, 4-METILBUTILO, N-PENTILO, NEOPENTILO, FENILO, BENCILO, FENETILO, 2-ETILBUTILO, 1-1-DIFLUOROBUTILO, N-METILAMIDO, N-METIL-N-TERTBUTILAMIDO, 2-METILFENILO, 2-ISOPROPILFENILO, 2-METOXIFENILO, 2-CLOROFENILO, 2,6-DIFLUOROFENILO, CICLOHEXILO, CICLOHEXILMETILO, 3-BUTENILO, 3-BUTINILO Y 2-HIDROXIBUTILO; EN DONDE R2 SE SELECCIONA DE ETILO, N-PROPILO, ISOPROPILO, N-BUTILO, SEC-BUTILO, ISOBUTILO, 4-METILBUTILO, ETILBUTILO, N-PENTILO, 1-OXO-2-FENILETILO, 1-OXO-2-CICLOHEXILETILO, 1,1-DIFLUORO-2-FENILETILO, 1,1-DIFLUORO-2-CICLOHEXILETILO, 2-CICLOHEXILETILO, 1,1-DIFLUORO-3-CICLOHEXILPROPILO, 1,1-DIMETOXIBUTILO, 1,1-DIFLUOROETILO, 1,1-DIFLUOROPROPILO, 1,1-DIFLUOROBUTILO, 1,1-DIFLUOROPENTILO, FENILO, BENCILO, 2-FENILETILO, 1,1-DIFLUORO-3-FENILPROPILO, CICLOHEXILMETILO, CICLOHEXANOILO, N-METILAMIDO, N-METIL-N-TERBUTILAMIDO, 2-METILFENILO, 2-ISOPROPILFENILO, 2-METOXIFENILO, 2-CLOROFENILO, 2,6-DIFLUOROFENILO, 1-BUTENILO, 2-BUTENILO, 3-BUTENILO, 1-BUTINILO, 2-BUTINILO, 3-BUTINILO, PROPILTIO Y BUTILTIO; EN DONDE R5 ES UN GRUPO ACIDO SELECCIONADO DE CO2H Y RADICALES TETRAZOLO; O UN TAUTOMERO DE ELLOS O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ELLOS.
ES92914808T 1991-04-12 1992-04-10 Productos de 1h-1,2,4-triazol substituidos por arilheteroarilalquilo en 1 para el tratamiento de trastornos circulatorios. Expired - Lifetime ES2088584T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/686,324 US5155117A (en) 1991-04-12 1991-04-12 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders

Publications (1)

Publication Number Publication Date
ES2088584T3 true ES2088584T3 (es) 1996-08-16

Family

ID=24755845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92914808T Expired - Lifetime ES2088584T3 (es) 1991-04-12 1992-04-10 Productos de 1h-1,2,4-triazol substituidos por arilheteroarilalquilo en 1 para el tratamiento de trastornos circulatorios.

Country Status (12)

Country Link
US (3) US5155117A (es)
EP (2) EP0619819B1 (es)
JP (1) JP3150149B2 (es)
AT (1) ATE139229T1 (es)
AU (1) AU650565B2 (es)
CA (1) CA2104795C (es)
DE (1) DE69211568T2 (es)
DK (1) DK0619819T3 (es)
ES (1) ES2088584T3 (es)
GR (1) GR3020219T3 (es)
IE (1) IE921157A1 (es)
WO (1) WO1992018092A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280887B6 (sk) * 1991-11-18 2000-09-12 E. I. Du Pont De Nemours And Company Spôsob výroby tetrazolylbifenylových zlúčenín a medziprodukty tohto spôsobu
DE4314964A1 (de) * 1993-05-06 1994-11-10 Bayer Ag Pyridinylmethyl-substiutierte Pyridine und Pyridone
DE4316077A1 (de) * 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
DE4320432A1 (de) * 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
CN1114593C (zh) * 1998-05-08 2003-07-16 陶氏益农有限责任公司 2位被取代的吡啶的制备
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
UA128288C2 (uk) 2018-03-08 2024-05-29 Інсайт Корпорейшн СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2461406C2 (de) * 1974-12-24 1984-06-14 Bayer Ag, 5090 Leverkusen Azolyl-(1)-methane und deren Salze, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE2851086A1 (de) * 1978-11-25 1980-06-04 Bayer Ag Hydroxypropyl-triazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2912288A1 (de) * 1979-03-28 1980-10-09 Bayer Ag Verfahren zur herstellung von hydroxyethyl-azolen
IL69407A (en) * 1982-08-23 1987-10-20 Warner Lambert Co 2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4742068A (en) * 1986-06-09 1988-05-03 Mcneilab, Inc. Dihydropyridine compounds having 1,4,4-trisubstitution useful as antihypertensive agents
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5075324A (en) * 1986-12-24 1991-12-24 Boehringer Biochemia Robin S.P.A. Aralkyl-1,4-dihydropyridines, a method for their preparation and pharmaceutical composition containing them
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US4845231A (en) * 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
DE3810848A1 (de) * 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung

Also Published As

Publication number Publication date
ATE139229T1 (de) 1996-06-15
AU2264692A (en) 1992-11-17
DK0619819T3 (da) 1996-07-15
US5602153A (en) 1997-02-11
CA2104795C (en) 2002-08-27
JP3150149B2 (ja) 2001-03-26
JPH06506953A (ja) 1994-08-04
EP0508445A1 (en) 1992-10-14
DE69211568D1 (de) 1996-07-18
EP0619819B1 (en) 1996-06-12
IE921157A1 (en) 1992-10-21
WO1992018092A3 (en) 1992-12-10
CA2104795A1 (en) 1992-10-13
EP0508445B1 (en) 1996-06-12
WO1992018092A2 (en) 1992-10-29
US5563139A (en) 1996-10-08
GR3020219T3 (en) 1996-09-30
US5155117A (en) 1992-10-13
DE69211568T2 (de) 1997-01-09
AU650565B2 (en) 1994-06-23
EP0619819A1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
ES2088584T3 (es) Productos de 1h-1,2,4-triazol substituidos por arilheteroarilalquilo en 1 para el tratamiento de trastornos circulatorios.
DE69229341D1 (de) N-arylheteroarylalkylimidazol-2-onverbindungen für die behandlung von kreislaufstörungen
ES2125868T3 (es) Compuestos de 1,2,4-triazol 1h-sustituidos para el tratamiento de trastornos cardiovasculares.
AU8867291A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
KR950704296A (ko) 약물학적 활성 피리딘 유도체 및 그의 제조 방법(Pharmacologically Active Pyridine Derivatives and Processes for the Preparation Thereof)
EP0902007A4 (en) CHALCON DERIVATIVES AND MEDICINES THAT CONTAIN THEM
EP0516392A3 (en) Naphthyridine derivatives as angiotensin ii inhibitors
CA2105867A1 (en) Novel imidazole derivatives, their preparation and therapeutic applications
EP0323841A3 (en) Substituted pyrrole, pyrazole and triazole angiotensin ii antagonists
DE3684431D1 (de) Derivate des ((4-(4-(4-phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2yl)methyl)-1h-imidazol und 1h-1,2,4-triazol.
ES2148496T3 (es) Combinaciones de sustancias activas para la inhibicion o regulacion de la nitrificacion.
EP0910948A3 (de) Fungizide Mischung
DE3460055D1 (en) Triazole antifungal agents
ES2143505T3 (es) Compuestos de n-arilheteroarilalquil-1-fenil-imidazol-2-ona para el tratamiento de trastornos circulatorios.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619819

Country of ref document: ES